Company profile: Cerebral Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapies and technology for direct-to-brain drug delivery, including CT-010, a proprietary valproic acid formulation delivered via an implanted, refillable catheter and pump for refractory epilepsy; the ICVRx platform enabling intracerebroventricular delivery of drugs, biologics, and oligonucleotide therapies; and clinical trials evaluating therapies for neurological diseases.
Products and services
- ICVRx™ Platform: Proprietary technology that enables direct-to-brain delivery of drugs, biologics, and oligonucleotides, bypassing the blood-brain barrier for targeted intracerebral therapy of neurological diseases
- CT-010: Proprietary valproic acid formulation delivered directly into the brain via an implanted, refillable catheter and pump system to treat refractory epilepsy
- Intracerebroventricular (ICV) Therapies: Specialized method administering drugs directly into the brain's ventricles to enhance distribution and reduce systemic side effects in treating neurological diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cerebral Therapeutics
Memory Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development of drug candidates for central nervous system conditions, including neurological diseases associated with aging (such as Alzheimer's disease) and psychiatric disorders such as schizophrenia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Memory Pharmaceuticals company profile →
Seelos Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics, including: SLS-002 intranasal ketamine for acute suicidal ideation/behavior in MDD and PTSD; SLS-005 IV trehalose for ALS and spinocerebellar ataxia; SLS-009 targeting mutant/misfolded proteins in Huntington’s and Alzheimer’s via autophagy; SLS-004 SNCA gene therapy for Parkinson’s; SLS-007 peptide targeting alpha-synuclein aggregation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seelos Therapeutics company profile →
Psyadon
HQ: United States
Website
- Description: Provider of discovery and development of new treatments for serious psychiatric and neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Psyadon company profile →
Neuros Medical
HQ: United States
Website
- Description: Provider of neurostimulation therapies for patients with unmet medical needs, including the Altius System, a device designed to alleviate chronic post-amputation pain using bioelectric nerve block technology targeting sensory nerves; a patented on-demand high-frequency bioelectric nerve block to block pain signals in sensory nerves; and the QUEST Study, a clinical trial evaluating the safety and effectiveness of the Altius System for treating intractable post-amputation pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuros Medical company profile →
Tryp Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage psilocybin-based therapeutics, developing an IV infusion of psilocin and synthetic oral psilocybin to address neuropsychiatric disorders, orphan diseases, and conditions with no effective first-line treatments. Offerings include TRP-8803, a proprietary IV psilocin formulation, TRP-8802 in early-stage trials, and Phase 2a studies in fibromyalgia, binge eating disorder, and irritable bowel syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tryp Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cerebral Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cerebral Therapeutics
2.2 - Growth funds investing in similar companies to Cerebral Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cerebral Therapeutics
4.2 - Public trading comparable groups for Cerebral Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →